{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:02:14Z","timestamp":1788566534194,"version":"build-2803163510"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The objectives of this study were to identify key treatment attributes that drive physician and patient preferences for second line (2L) and third line (3L) treatments in relapsed\/refractory (R\/R) follicular lymphoma (FL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multi- country, internet-based survey was administered to patients(N=195) with R\/R FL and treating physicians (N=300) from the United States, United Kingdom, France, Germany, Brazil, and Japan. The survey included two discrete choice experiments \u2013 one for 2L and one for 3L treatment options \u2013 that prompted respondents to select their preferred option between two hypothetical treatment profiles varying on seven attributes associated with treatment for R\/RFL: progression-free survival (PFS), overall survival (OS), serious adverse events (AE), cytokine release syndrome (CRS) events, neurological events, fatigue, and administration. Mean preference weights and relative attribute importance were estimated in each sample, overall and by country, using hierarchical Bayesian models.  Physician estimates were also stratified by practice setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment preferences for physicians and patients were most influenced by PFS. Beyond PFS, patients placed greater emphasis on the administration of medications, whereas physicians tended to focus more on five-year OS and toxicity profiles of agents. Preference for PFS above all other 2L and 3L treatment attributes was consistent for physicians, regardless of practice setting and country. However, patient treatment preferences varied by country.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These results offer key perspectives on how physicians and patients evaluate treatment options in 2L and 3L treatment settings; this information is essential for facilitating shared decision-making in an expanding, complex treatment landscape.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1589722","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T05:30:17Z","timestamp":1752125417000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Patient and physician treatment preferences in relapsed\/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan"],"prefix":"10.3389","volume":"15","author":[{"given":"John G.","family":"Gribben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markqayne","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Krupsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Beusterien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Kopenhafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Beygi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Best","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Will","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Palivela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ghione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"B1","unstructured":"Oracle Life Sciences\n          Treatment architecture\n          \n          2024"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02882-1","article-title":"Quality of life evaluation in patients with follicular cell lymphoma: A real-world study in europe and the United States","volume":"41","author":"Johnson","year":"2024","journal-title":"Adv Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.2014.93.issue-3","article-title":"Impact of therapy and disease-related symptoms on health-related quality of life in patients with follicular lymphoma: results of the population-based PHAROS-registry","volume":"93","author":"Oerlemans","year":"2014","journal-title":"Eur J Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm543","article-title":"The impact of follicular lymphoma on health-related quality of life","volume":"19","author":"Pettengell","year":"2008","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.3390\/cancers15153885","article-title":"Factors affecting health-related quality of life among survivors of non-hodgkin lymphoma: A population-based study","volume":"15","author":"Wasse","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/pon.v18:5","article-title":"The impact of follicular (FL) and other indolent non-Hodgkin\u2019s lymphomas (NHL) on work productivity-a preliminary analysis","volume":"18","author":"Cheung","year":"2009","journal-title":"Psychooncology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2165\/11314820-000000000-00000","article-title":"Economic burden of follicular non-Hodgkin\u2019s lymphoma","volume":"27","author":"Foster","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0267","article-title":"Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA","volume":"14","author":"Morrison","year":"2018","journal-title":"Future Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2217\/cer-2018-0094","article-title":"Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA","volume":"8","author":"Ren","year":"2019","journal-title":"J Comp Eff Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","article-title":"Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus (131)I-tositumomab: long-term follow-up of phase III randomized study SWOG-S0016","volume":"36","author":"Shadman","year":"2018","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04126-y","article-title":"A multi-center retrospective analysis of patients with relapsed\/refractory follicular lymphoma after third-line chemotherapy","volume":"99","author":"Fuji","year":"2020","journal-title":"Ann Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.2019.184.issue-5","article-title":"Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era","volume":"184","author":"Rivas-Delgado","year":"2019","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000919","article-title":"Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: final results from the GALLIUM study","volume":"7","author":"Townsend","year":"2023","journal-title":"Hemasphere"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14335","article-title":"Comparative analysis of bispecific antibodies and CAR T-cell therapy in follicular lymphoma","volume":"114","author":"Morabito","year":"2024","journal-title":"Eur J Haematol"},{"key":"B17","article-title":"Current trends in diagnosis and management of follicular lymphoma","volume":"12","author":"Gupta","year":"2022","journal-title":"Am J Blood Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-013-0023-3","article-title":"Patient preferences versus physicians\u2019 judgement: does it make a difference in healthcare decision making","volume":"11","author":"M\u00fchlbacher","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.006","article-title":"Patient-focused benefit-risk analysis to inform regulatory decisions: the european union perspective","volume":"19","author":"M\u00fchlbacher","year":"2016","journal-title":"Value Health"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e389516","DOI":"10.1200\/EDBK_389516","article-title":"Shared decision making in the care of patients with cancer","volume":"43","author":"Shickh","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3390\/jpm12060879","article-title":"Patient and clinician preferences for genetic and genomic testing in non-small cell lung cancer: A discrete choice experiment","volume":"12","author":"Fifer","year":"2022","journal-title":"J Pers Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1370\/afm.3011","article-title":"Patient communication preferences for prostate cancer screening discussions: A scoping review","volume":"21","author":"Fong","year":"2023","journal-title":"Ann Fam Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S125245","article-title":"Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment","volume":"9","author":"Gonz\u00e1lez","year":"2017","journal-title":"Cancer Manag Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3944-9","article-title":"A discrete choice experiment to assess cancer patients\u2019 preferences for when and how to make treatment decisions","volume":"26","author":"Herrmann","year":"2018","journal-title":"Support Care Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2217\/fon-2021-0567","article-title":"Patients\u2019 and oncologists\u2019 preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer","volume":"18","author":"Stone","year":"2022","journal-title":"Future Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S432821","article-title":"Understanding patient preferences regarding the important determinants of breast cancer treatment: A narrative scoping review","volume":"17","author":"Yeo","year":"2023","journal-title":"Patient Prefer Adherence"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1186\/s12885-023-11598-4","article-title":"Differences between physician and patient preferences for cancer treatments: a systematic review","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.225","article-title":"Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment","volume":"46","author":"Shafey","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v13.19","article-title":"Preferences of patients and physicians in the United States for relapsed\/refractory follicular lymphoma treatments","volume":"13","author":"Thomas","year":"2024","journal-title":"Cancer Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.004","article-title":"Statistical methods for the analysis of discrete choice experiments: A report of the ISPOR conjoint analysis good research practices task force","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","article-title":"Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force","volume":"16","author":"Reed Johnson","year":"2013","journal-title":"Value Health"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2196\/32365","article-title":"Understanding uptake of digital health products: methodology tutorial for a discrete choice experiment using the bayesian efficient design","volume":"23","author":"Szinay","year":"2021","journal-title":"J Med Internet Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.762977","article-title":"A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Lymphoma Symptom Index","volume":"54","author":"Hlubocky","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B37","doi-asserted-by":"publisher","first-page":"147176","DOI":"10.1155\/2013\/147176","article-title":"The development and validation of a measure of health-related quality of life for non-hodgkin\u2019s lymphoma: the functional assessment of cancer therapy\u2014Lymphoma (FACT-lym)","volume":"2013","author":"Hlubocky","year":"2013","journal-title":"Lymphoma"},{"key":"B38","volume-title":"Getting started with conjoint analysis: strategies for product design and pricing research","author":"Orme","year":"2010"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7571","article-title":"Progression-free survival: meaningful or simply measurable","volume":"10","author":"Booth","year":"2012","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30210-2","article-title":"The science of hope","volume":"9","author":"Corn","year":"2020","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.12968\/hmed.2019.80.1.33","article-title":"Haematopoietic stem cell transplants: principles and indications","volume":"80","author":"Balassa","year":"2019","journal-title":"Br J Hosp Med (Lond)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"293.e15","DOI":"10.1016\/j.urolonc.2023.01.020","article-title":"The effect of treatment on work productivity in patients with bladder cancer","volume":"41","author":"Ahlschlager","year":"2023","journal-title":"Urol Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2014.08.004","article-title":"Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study","volume":"23","author":"Cleeland","year":"2014","journal-title":"Breast"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1707213","article-title":"A population-based study of the humanistic burden among cancer patients in Japan","volume":"23","author":"Ohno","year":"2020","journal-title":"J Med Econ"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02152-6","article-title":"The humanistic burden of advanced non-small cell lung cancer (NSCLC) in Europe: a real-world survey linking patient clinical factors to patient and caregiver burden","volume":"28","author":"Wood","year":"2019","journal-title":"Qual Life Res"},{"key":"B46","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-007-7596-1_3","article-title":"Population norms for the EQ-5D","volume-title":"Self-reported population health: an international perspective based on EQ-5D","author":"Janssen","year":"2014"},{"key":"B47","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12955-021-01671-6","article-title":"EQ-5D Brazilian population norms","volume":"19","author":"Santos","year":"2021","journal-title":"Health Qual Life Outcomes"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1589722\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T05:30:19Z","timestamp":1752125419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1589722\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":47,"alternative-id":["10.3389\/fonc.2025.1589722"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1589722","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"article-number":"1589722"}}